This meta-analysis examines the association of cardioprotective glucose-lowering agents, including glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors, with reductions in dementia and cognitive impairment. This evidence concerns the gene SLC5A2 and Cognitive impairment.